J. Hanson

发表

Deorphanization of GPR109B as a Receptor for the β-Oxidation Intermediate 3-OH-octanoic Acid and Its Role in the Regulation of Lipolysis*

S. Tunaru, S. Offermanns, S. Kölker, 2009, The Journal of Biological Chemistry.

Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7.

J. Piette, A. Baragli, J. Hanson, 2016, Biochemical pharmacology.

Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin.

S. Offermanns, J. Hanson, A. Gille, 2012, Pharmacology & therapeutics.

Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.

S. Tunaru, S. Offermanns, J. Hanson, 2011, Trends in pharmacological sciences.

Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.

S. Tunaru, A. Wirth, S. Offermanns, 2010, The Journal of clinical investigation.

Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.

P. Kolh, P. Segers, B. Lambermont, 2006, Prostaglandins & other lipid mediators.

Effects of BM-573, a thromboxane A2 modulator on systemic hemodynamics perturbations induced by U-46619 in the pig.

P. Kolh, B. Lambermont, J. Dogné, 2005, Prostaglandins & other lipid mediators.

Effects of Dobutamine on Left Ventriculoarterial Coupling and Mechanical Efficiency in Acutely Ischemic Pigs

P. Kolh, B. Lambermont, J. Dogné, 2005, Journal of cardiovascular pharmacology.

The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment

S. Niclou, N. Heveker, B. Janji, 2019, Cells.

Succinate receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Wen Chiy Liew, A. Davenport, J. Hanson, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Superconserved receptors expressed in the brain: Expression, function, motifs and evolution of an orphan receptor family.

J. Hanson, Claudia Stäubert, M. Woźniak, 2022, Pharmacology & therapeutics.

Update on GPIIb/IIIa antagonists

P. Kolh, C. Supuran, J. Dogné, 2003 .

Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis.

D. Praticò, J. Dogné, J. Hanson, 2005, Trends in pharmacological sciences.

Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts.

J. Hanson, Thanigaimalai Pillaiyar, S. Laufer, 2022, Future medicinal chemistry.

Coxibs and cardiovascular side-effects: from light to shadow.

D. Praticò, C. Supuran, J. Dogné, 2006, Current pharmaceutical design.

Chemokine neutralization as an innovative therapeutic strategy for atopic dermatitis.

J. Hanson, Dayana Abboud, 2017, Drug discovery today.

Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non‐chemokine agonists

J. Steyaert, J. Hanson, M. Meyrath, 2018, Biochemical pharmacology.

Heterologously expressed formyl peptide receptor 2 (FPR2/ALX) does not respond to lipoxin A₄.

N. Ferreirós, S. Offermanns, B. Pirotte, 2013, Biochemical pharmacology.

Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators—What is the Evidence so far?

G. FitzGerald, D. Steinhilber, K. Weylandt, 2022, Frontiers in Pharmacology.

BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.

L. de Leval, B. Masereel, S. Rolin, 2011, Prostaglandins & other lipid mediators.

Succinate receptor in GtoPdb v.2021.3

Wen Chiy Liew, A. Davenport, J. Hanson, 2021, IUPHAR/BPS Guide to Pharmacology CITE.

Effect of BM-573 [N-Terbutyl-N′-[2-(4′-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, in a Porcine Model of Acute Pulmonary Embolism

P. Kolh, P. Segers, B. Lambermont, 2004, Journal of Pharmacology and Experimental Therapeutics.

Effect of BM-573, a dual thromboxane synthase inhibitor and TP receptor antagonist, in a porcine model of acute pulmonary embolism

P. Kolh, P. Segers, B. Lambermont, 2004 .

BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.

D. Praticò, B. Masereel, S. Rolin, 2007, Prostaglandins & other lipid mediators.

Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.

B. Masereel, S. Rolin, J. Dogné, 2004, Prostaglandins & other lipid mediators.

Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig.

P. Kolh, P. Segers, B. Lambermont, 2005, Thrombosis research.

In Vitro and in Vivo Pharmacological Characterization of BM-613 [N-n-Pentyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a Novel Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist

B. Masereel, S. Rolin, J. Dogné, 2005, Journal of Pharmacology and Experimental Therapeutics.

In vitro and in vivo pharmacological characterization of BM-613, a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist

B. Masereel, S. Rolin, J. Dogné, 2004 .

Pharmacological Characterization of N-tert-Butyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a Novel Thromboxane A2 Receptor Antagonist and Thromboxane Synthase Inhibitor in a Rat Model of Arterial Thrombosis and Its Effects on Bleeding Time

P. Kolh, P. Segers, L. de Leval, 2004, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological characterization of BM-573, a novel thromboxane A 2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time

P. Kolh, P. Segers, B. Masereel, 2004 .

Nanolu0ciferase-Based Complementation Assay to Detect GPCR-G Protein Interaction.

J. Hanson, Céline Laschet, C. Laschet, 2021, Methods in molecular biology.

GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11

M. Bahri, A. Plenevaux, A. Inoue, 2020, Nature Communications.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview

Arthur Christopoulos, Christopher Southan, Stephen PH Alexander, 2017, British journal of pharmacology.

Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D2L receptor

E. Hermans, J. Hanson, Mattia Ferraiolo, 2022, Fundamental & clinical pharmacology.

The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B

B. Janji, B. Volkman, T. Laeremans, 2022, Frontiers in Immunology.

Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.

P. Kolh, P. Chiap, B. Lambermont, 2006, Cardiovascular drug reviews.

Cardiovascular haemodynamics and ventriculo‐arterial coupling in an acute pig model of coronary ischaemia–reperfusion

P. Kolh, P. Verdonck, P. Segers, 2007, Experimental physiology.

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

Stephen P. H. Alexander, Leigh A. Stoddart, Kalyan C. Tirupula, 2021, British journal of pharmacology.

Enhancing Action of Positive Allosteric Modulators through the Design of Dimeric Compounds.

J. Kastrup, S. Dilly, B. Pirotte, 2018, Journal of medicinal chemistry.

7-Phenoxy-Substituted 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxides as Positive Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors with Nanomolar Potency.

P. Tullio, C. Ptak, R. Oswald, 2018, Journal of medicinal chemistry.

Alternative glycosylation controls endoplasmic reticulum dynamics and tubular extension in mammalian cells

M. Vidal, J. Lambert, D. Vertommen, 2021, Science Advances.

Exostosin-1 Glycosyltransferase Regulates Endoplasmic Reticulum Architecture and Dynamics

M. Vidal, J. Lambert, D. Vertommen, 2020, bioRxiv.

Identification and pharmacological characterization of succinate receptor agonists

F. Jouret, A. Inoue, S. Dilly, 2017, British journal of pharmacology.

Insight into SUCNR1 (GPR91) structure and function.

F. Jouret, B. Pirotte, J. Hanson, 2016, Pharmacology & therapeutics.

Forskolin-free cAMP assay for Gi-coupled receptors.

B. Pirotte, J. Hanson, Nadine Dupuis, 2015, Biochemical pharmacology.

An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81.

S. Tunaru, S. Offermanns, Cong Tang, 2010, Cell metabolism.

Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A₂ receptor antagonists.

P. Kolh, J. Dogné, B. Pirotte, 2013, European journal of medicinal chemistry.

The G protein‐coupled receptors deorphanization landscape

J. Hanson, Céline Laschet, Nadine Dupuis, 2018, Biochemical pharmacology.

GPCRs in immunity: Atypical receptors and novel concepts.

J. Hanson, A. Chevigné, 2016, Biochemical pharmacology.

The causes and consequences of pituitary gigantism

A. Beckers, J. Hanson, A. Daly, 2018, Nature Reviews Endocrinology.

β‐arrestin2 recruitment at the β2 adrenergic receptor: A luciferase complementation assay adapted for undergraduate training in pharmacology

L. Ruiz, E. Hermans, J. Hanson, 2021, Pharmacology research & perspectives.

A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR–G protein interactions

J. Hanson, Nadine Dupuis, Céline Laschet, 2018, The Journal of Biological Chemistry.

New insights in the development of positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors belonging to 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides: Introduction of (mono/difluoro)methyl groups at the 2-position of the thiadiazine ring.

L. Danober, B. Pirotte, J. Hanson, 2023, European journal of medicinal chemistry.

From the design to the clinical application of thromboxane modulators.

Bernard Pirotte, Pierre Drion, D. Praticò, 2006, Current pharmaceutical design.

Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27.

C. Müller, T. Kronenberger, J. Hanson, 2021, European journal of medicinal chemistry.

Different contributions of chemokine N‐terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3

N. Heveker, B. Volkman, Amanda M. Nevins, 2017, British journal of pharmacology.

New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators.

B. Masereel, J. Dogné, J. David, 2004, Current medicinal chemistry.

New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators.

P. Kolh, A. Casini, B. Lambermont, 2004, Current medicinal chemistry.

Activation of the Orphan G Protein–Coupled Receptor GPR27 by Surrogate Ligands Promotes β-Arrestin 2 Recruitment

J. Twizere, A. Soni, D. Franssen, 2017, Molecular Pharmacology.

New developments on thromboxane modulators.

P. Kolh, B. Masereel, J. Dogné, 2004, Mini reviews in medicinal chemistry.

Dopamine D2L receptor density influences the recruitment of β-arrestin2 and Gi1 induced by antiparkinsonian drugs

E. Hermans, J. Hanson, Mattia Ferraiolo, 2022, Neuropharmacology.